La Chaux-de-Fonds, Switzerland, March 26, 2019 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A. announces poster presentation of RP4010, a novel first-in-class CRAC channel inhibitor in preclinical models of Gastrointestinal (GI) cancers.

Highlights from the poster include: 

•  Treatment of GI cancer cell lines with single-agent RP4010 decreased cell growth 
•  RP4010 synergized with gemcitabine and nab-paclitaxel in Pancreatic Ductal Adenocarcinoma (PDAC)
•  RP4010 synergized with nab-paclitaxel in Gastric Cancer (GC)
•  RP4010 significantly enhanced the activity of everolimus in Pancreatic Neuroendocrine Tumors (PNETs)

About RP4010:

RP4010 is a novel first-in-class oral small molecule inhibitor of calcium release activated calcium (CRAC) channel pathway with demonstrated preclinical activity in a broad range of cancers.  Blockade of store-operated calcium entry (SOCE) through CRAC channel inhibition could suppress tumor growth via a number of downstream events including inhibition of NFAT dephosphorylation as well as calcium-dependent activation of Akt/NF-kB and ERK 1/2 pathways.  A multi-center Phase I/IB dose-escalation trial evaluating the safety and efficacy of RP4010, a CRAC channel inhibitor in patients with relapsed or refractory Lymphomas is currently ongoing in USA and Australia (ClinicalTrials.gov Identifier: NCT03119467).

Details of the poster presentation:

-- Poster Title:  Efficacy of RP4010, a calcium release-activated calcium (CRAC) channel inhibitor, in preclinical models of gastrointestinal cancers

• Session Category:                  Experimental and Molecular Therapeutics
• Session Title:                          Novel Antitumor Agents 1
• Session Date & Time:             Tuesday, April 2, 2019; 8:00 AM – 12:00 PM
• Location:                                 Georgia World Congress Center, Exhibit Hall B, Poster Section 14
• Poster Board Number:            3
• Permanent Abstract No.:        3069

About Rhizen Pharmaceuticals S.A.:

Rhizen Pharmaceuticals is an innovative, clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of cancer, immune and metabolic disorders.  Since its establishment in 2008, Rhizen has created a diverse pipeline of proprietary drug candidates targeting several cancers and immune associated cellular pathways.  Rhizen is headquartered in La-Chaux-de-Fonds, Switzerland.  For additional information, please visit Rhizen’s website, www.rhizen.com.

Kumar V. Penmetsa, Ph.D.
Executive Vice President, Corporate Development
Rhizen Pharmaceuticals S.A.
Telephone: +1-267-207-5707
Email:  kvp@rhizen.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.